SNGX 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

SNGX ▼ -47.25% at T+5d

SHORT call ✓ call won +47.25% · α vs SPY +46.96% · entry $0.9100 → $0.4800

Next anchor: T+20d in 13d

Currently $0.4300 · +52.75% from $0.9100 entry (call sign-flipped)

Entry anchored
May 28, 03:59 PM ET
via Databento tick

T+1d

-9.31%

call +9.31% · α +9.58%

$0.8253

settled 15d ago

T+5d

-47.25%

call +47.25% · α +46.96%

$0.4800

settled 9d ago

T+20d

—

call — · α —

—

in 13d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Soligenix filed an 8-K to increase the maximum aggregate offering amount under its existing at-the-market (ATM) equity facility with Rodman & Renshaw by $2,956,000, bringing the total to $6,406,000. The company had previously sold approximately $3,445,000 under the facility. This represents ongoing equity dilution for a micro-cap biotech with a $13M market cap.

Actionable Insight

The ATM increase signals ongoing cash needs and likely continued dilution. With $3.4M already sold and a $13M market cap, the company is relying on equity financing to fund operations. Monitor upcoming quarterly filings for cash runway and any pipeline catalysts that could alter the dilution trajectory.

Key Facts

ATM facility increased by $2,956,000 to a total maximum of $6,406,000
Prior sales under the facility totaled approximately $3,445,000
Shares sold through Rodman & Renshaw under the existing Sales Agreement dated January 23, 2026
Company market cap is approximately $13M, making the incremental offering ~23% of market cap

Financial Impact

Potential additional dilution of up to $2.96M in gross proceeds, representing ~23% of current $13M market cap

dilution

Risk Factors

Further dilution from continued ATM sales
Potential inability to raise sufficient capital if stock price declines
No disclosed revenue or near-term catalyst to offset dilution

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-067649
Document: sngx-20260528xex23d1.htm	0001104659-26-067649
Document: sngx-20260528xex5d1.htm	0001104659-26-067649
Document: 0001104659-26-067649-index-headers.html	0001104659-26-067649
Document: 0001104659-26-067649-index.html	0001104659-26-067649
Document: 0001104659-26-067649.txt	0001104659-26-067649

3 reports for SNGX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SNGX — sortable, filterable
	Type				Now
May 28, 2026 15d ago	8-K BEARISH ★ 5/10	$0.9100 $0.4800	▲ +47.25%	▲ +46.96%	$0.4300 (+52.75%)
May 28, 2026 15d ago	424B5 BEARISH ★ 6/10	$0.9100 $0.4800	▲ +47.25%	▲ +46.96%	$0.4300 (+52.75%)
Apr 3, 2026 10w ago	EFFECT BEARISH ★ 6/10	$1.14 $1.15	▼ −0.88%	▲ +3.26%	$0.4300 (+62.28%)

US Market Status

Market Closed — Opens Mon (47h 36m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access